BR0315912A - Compostos pirimìdicos com atividade antiproliferativa (ii) - Google Patents

Compostos pirimìdicos com atividade antiproliferativa (ii)

Info

Publication number
BR0315912A
BR0315912A BR0315912-4A BR0315912A BR0315912A BR 0315912 A BR0315912 A BR 0315912A BR 0315912 A BR0315912 A BR 0315912A BR 0315912 A BR0315912 A BR 0315912A
Authority
BR
Brazil
Prior art keywords
compounds
antiproliferative activity
pyrimidine compounds
antiproliferative
pyrimidine
Prior art date
Application number
BR0315912-4A
Other languages
English (en)
Inventor
Kin-Chun Luk
Pamela Loreen Rossman
Stefan Scheiblich
Sung-Sau So
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0315912A publication Critical patent/BR0315912A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

"COMPOSTOS PIRIMìDICOS COM ATIVIDADE ANTIPROLIFERATIVA (II)". A presente invenção refere-se a compostos pirimídicos inusitados da fórmula onde R¬ 1¬ a R¬ 2¬ são como definidos no relatório descritivo, e que são inibidores seletivos da família Src de tirosina cinases. Estes compostos e seus sais farmaceuticamente aceitáveis são agentes antiproliferativos úteis no tratamento ou controle de tumores sólidos, particularmente tumores de mama, cólon, fígado e pâncreas. Descreve-se também composições farmacêuticas que contêm estes compostos e o uso para tratar câncer.
BR0315912-4A 2002-11-04 2003-10-27 Compostos pirimìdicos com atividade antiproliferativa (ii) BR0315912A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42367002P 2002-11-04 2002-11-04
PCT/EP2003/011892 WO2004041821A1 (en) 2002-11-04 2003-10-27 Pyrimido compounds having antiproliferative activity (ii)

Publications (1)

Publication Number Publication Date
BR0315912A true BR0315912A (pt) 2005-09-13

Family

ID=32312700

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0316001-7A BR0316001A (pt) 2002-11-04 2003-10-27 Derivados de pirimido[4,5-d]pirimidina com atividade anticâncer
BR0315912-4A BR0315912A (pt) 2002-11-04 2003-10-27 Compostos pirimìdicos com atividade antiproliferativa (ii)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR0316001-7A BR0316001A (pt) 2002-11-04 2003-10-27 Derivados de pirimido[4,5-d]pirimidina com atividade anticâncer

Country Status (16)

Country Link
US (2) US7129351B2 (pt)
EP (2) EP1560832B1 (pt)
JP (2) JP2006513999A (pt)
KR (4) KR100774231B1 (pt)
CN (2) CN100420688C (pt)
AR (2) AR041738A1 (pt)
AT (2) ATE386744T1 (pt)
AU (1) AU2003276190A1 (pt)
BR (2) BR0316001A (pt)
CA (2) CA2502180A1 (pt)
DE (2) DE60318888T2 (pt)
ES (2) ES2298622T3 (pt)
MX (2) MXPA05004756A (pt)
PL (2) PL376924A1 (pt)
RU (2) RU2331641C2 (pt)
WO (2) WO2004041821A1 (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003903501A0 (en) * 2003-07-07 2003-07-24 Commonwealth Scientific And Industrial Research Organisation A method of forming a reflective authentication device
AU2004260689B8 (en) 2003-07-29 2008-05-15 Irm Llc Compounds and compositions as protein kinase inhibitors
FR2873127B1 (fr) 2004-07-13 2008-08-29 Omya Development Ag Procede de fabrication de particules pigmentaires autoliantes, seches ou en suspension ou dispersion aqueuses, contenant des matieres inorganiques et des liants
RU2007111758A (ru) 2004-08-31 2008-10-10 Ф.Хоффманн-Ля Рош Аг (Ch) Аминопроизводные 7- амино-3-фенилдигидропиримидо [4,5-d] пиримидинонов, их получение и применение в качестве ингибиторов протеинкиназ
WO2006024486A2 (en) * 2004-08-31 2006-03-09 F. Hoffmann-La Roche Ag Amide derivatives of 3-phenyl dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents
BR122021011787B1 (pt) * 2005-11-01 2022-01-25 Impact Biomedicines, Inc Inibidores de biaril meta pirimidina de cinases, composição farmacêutica e processo para preparar uma composição farmacêutica
AU2007211684A1 (en) 2006-01-31 2007-08-09 F. Hoffmann-La Roche Ag 7H-pyrido[3,4-d]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors
US7820826B2 (en) * 2006-03-29 2010-10-26 North Carolina State University Synthesis and regioselective substitution of 6-halo-and 6-alkoxy nicotine derivatives
US20090312321A1 (en) * 2006-05-15 2009-12-17 Irm Llc Compositions and methods for fgf receptor kinases inhibitors
US7897762B2 (en) * 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
MX2011001196A (es) * 2008-07-31 2011-05-30 Genentech Inc Compuestos de pirimidina, composiciones y metodos de uso.
MX2011002793A (es) 2008-09-25 2011-04-05 Hoffmann La Roche Derivados de 3-amino-indazol o de 3-amino-4,5,6,7-tetrahidro-indaz ol.
EP2376493B1 (en) 2008-12-12 2016-10-05 Msd K.K. Dihydropyrimidopyrimidine derivative
JP2012511501A (ja) 2008-12-12 2012-05-24 Ｍｓｄ株式会社 ジヒドロピリミドピリミジン誘導体
HUP0800768A2 (en) 2008-12-18 2012-08-28 Bioblocks Magyarorszag Gyogyszerkemiai Es Fejlesztoe Kft 1,3-heterocycles condensed with monoterpene skeleton, their use and pharmaceutical compositions comprising such compounds
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2401613A2 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2401614A1 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US20100318651A1 (en) * 2009-06-10 2010-12-16 Everis, Inc. Network Communication System With Monitoring
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
GB201204384D0 (en) 2012-03-13 2012-04-25 Univ Dundee Anti-flammatory agents
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
EP3822273B1 (en) 2012-06-13 2024-04-10 Incyte Holdings Corporation Substituted tricyclic compounds as fgfr inhibitors
EP2872161B1 (en) 2012-06-26 2020-12-16 Del Mar Pharmaceuticals Dianhydrogalactitol for use in treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
TWI647220B (zh) 2013-03-15 2019-01-11 美商西建卡爾有限責任公司 雜芳基化合物及其用途
CN105307657B (zh) 2013-03-15 2020-07-10 西建卡尔有限责任公司 杂芳基化合物和其用途
UA120248C2 (uk) 2013-03-15 2019-11-11 Селджен Кар Ллс Гетероарильні сполуки та їх застосування
SG10201708520YA (en) 2013-04-19 2017-12-28 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US9783504B2 (en) 2013-07-09 2017-10-10 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease
AU2015292818B2 (en) 2014-07-21 2020-01-16 Dana-Farber Cancer Institute, Inc. Imidazolyl kinase inhibitors and uses thereof
US10457691B2 (en) 2014-07-21 2019-10-29 Dana-Farber Cancer Institute, Inc. Macrocyclic kinase inhibitors and uses thereof
EP3536323A1 (en) 2014-08-08 2019-09-11 Dana Farber Cancer Institute, Inc. Uses of salt-inducible kinase (sik) inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MX2017010673A (es) 2015-02-20 2018-03-21 Incyte Corp Heterociclos biciclicos como inhibidores de receptores del factor de crecimiento fibroblastico (fgfr).
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
CN110225914A (zh) * 2016-07-05 2019-09-10 布罗德研究所股份有限公司 双环脲激酶抑制剂及其用途
WO2018053373A1 (en) 2016-09-16 2018-03-22 The General Hospital Corporation Uses of satl-inducible kinase (sik) inhibitors for treating osteoporosis
US11285158B2 (en) 2017-02-28 2022-03-29 The General Hospital Corporation Uses of pyrimidopyrimidinones as SIK inhibitors
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN112566912A (zh) 2018-05-04 2021-03-26 因赛特公司 Fgfr抑制剂的盐
CN112867716A (zh) 2018-05-04 2021-05-28 因赛特公司 Fgfr抑制剂的固体形式和其制备方法
EP3902804A1 (en) * 2018-12-27 2021-11-03 Les Laboratoires Servier SAS Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
AU2020366006A1 (en) 2019-10-14 2022-04-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
KR20220131900A (ko) 2019-12-04 2022-09-29 인사이트 코포레이션 Fgfr 억제제의 유도체
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2949466A (en) * 1958-03-04 1960-08-16 Parke Davis & Co Pyrimidine compounds and means of producing the same
NL6704601A (pt) * 1966-04-06 1967-10-09
US4425346A (en) 1980-08-01 1984-01-10 Smith And Nephew Associated Companies Limited Pharmaceutical compositions
JPS60226882A (ja) * 1984-04-24 1985-11-12 Nippon Zoki Pharmaceut Co Ltd 新規ピリミドピリミジン誘導体
WO1998024432A2 (en) 1996-12-05 1998-06-11 Sugen, Inc. Use of indolinone compounds as modulators of protein kinases
KR200143829Y1 (ko) * 1996-12-30 1999-06-15 양재신 연료펌프 교환시 연료의 비산 방지구
CN1138778C (zh) * 1998-05-26 2004-02-18 沃尼尔·朗伯公司 用作细胞增殖抑制剂的二环嘧啶及二环3,4-二氢嘧啶化合物及用途
CA2347474C (en) 1998-10-23 2008-08-26 F. Hoffmann-La Roche Ag Bicyclic nitrogen heterocycles
BR0015243A (pt) 1999-10-21 2002-07-16 Hoffmann La Roche Heterociclos de nitrogênio bicìclico substituìdos por heteroalquilamino como inibidores da proteìna cinase p38
CN1156477C (zh) 1999-10-21 2004-07-07 霍夫曼-拉罗奇有限公司 作为p38蛋白激酶的抑制剂的烷基氨基-取代的双环氮杂环类化合物
AR030053A1 (es) 2000-03-02 2003-08-13 Smithkline Beecham Corp 1h-pirimido [4,5-d] pirimidin-2-onas y sales, composiciones farmaceuticas, uso para la fabricacion de un medicamento y procedimiento para producirlas
CA2420286A1 (en) 2000-08-31 2002-03-07 F. Hoffmann-La Roche Ag 7-oxo pyridopyrimidines as inhibitors of a cellular proliferation
KR20060111716A (ko) 2002-01-22 2006-10-27 워너-램버트 캄파니 엘엘씨 2-(피리딘-2-일아미노)-피리도[2,3-ｄ]피리미딘-7-온
PA8577501A1 (es) * 2002-07-25 2004-02-07 Warner Lambert Co Inhibidores de quinasas
JP2006512313A (ja) 2002-10-31 2006-04-13 アムジェン インコーポレイテッド 抗炎症剤

Also Published As

Publication number Publication date
CN1711266A (zh) 2005-12-21
EP1560832B1 (en) 2008-01-23
WO2004041822A1 (en) 2004-05-21
ATE384725T1 (de) 2008-02-15
KR20070087689A (ko) 2007-08-28
AU2003274086B2 (en) 2008-07-10
KR100774231B1 (ko) 2007-11-07
RU2005117340A (ru) 2006-02-27
RU2331641C2 (ru) 2008-08-20
AU2003274086A1 (en) 2004-06-07
DE60319260D1 (de) 2008-04-03
ES2300609T3 (es) 2008-06-16
BR0316001A (pt) 2005-09-13
PL376916A1 (pl) 2006-01-09
RU2326882C2 (ru) 2008-06-20
US7129351B2 (en) 2006-10-31
DE60318888T2 (de) 2009-01-08
US7112676B2 (en) 2006-09-26
DE60318888D1 (de) 2008-03-13
AU2003276190A1 (en) 2004-06-07
US20040110773A1 (en) 2004-06-10
EP1560832A1 (en) 2005-08-10
KR100763300B1 (ko) 2007-10-04
PL376924A1 (pl) 2006-01-09
JP2006513999A (ja) 2006-04-27
CA2502180A1 (en) 2004-05-21
KR20050074540A (ko) 2005-07-18
KR20070087657A (ko) 2007-08-28
ATE386744T1 (de) 2008-03-15
WO2004041821A1 (en) 2004-05-21
AR041738A1 (es) 2005-05-26
MXPA05004757A (es) 2005-08-02
MXPA05004756A (es) 2005-08-02
JP2006507292A (ja) 2006-03-02
EP1560829B1 (en) 2008-02-20
KR100774230B1 (ko) 2007-11-07
DE60319260T2 (de) 2009-03-05
AR041739A1 (es) 2005-05-26
ES2298622T3 (es) 2008-05-16
KR20050074534A (ko) 2005-07-18
RU2005117341A (ru) 2006-03-10
CA2502182A1 (en) 2004-05-21
CN100420688C (zh) 2008-09-24
CN1711264A (zh) 2005-12-21
EP1560829A1 (en) 2005-08-10
KR100763299B1 (ko) 2007-10-04
US20050075272A1 (en) 2005-04-07

Similar Documents

Publication Publication Date Title
BR0315912A (pt) Compostos pirimìdicos com atividade antiproliferativa (ii)
BRPI0409366A (pt) compostos de pirimido
BR0313732A (pt) Compostos de pirimido tendo atividade antiproliferativa
MXPA05007352A (es) Compuestos triciclicos inhibidores de proteina quinasa para mejorar la eficacia de agentes antineoplasicos y terapia de radiacion.
MY141739A (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
BR0208907A (pt) Composto uso de um composto, composição farmacêutica, métodos para a terapia da dor em um animal de sangue quente e para a redução seletiva de uma porção nitro orto para um substituinte amino em um anel fenila ou piridila de um composto.
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
BRPI0117360B8 (pt) inibidores de proteína de quinase de 2-indolinona de pirrol substituído, seus sais e composições farmacêuticas compreendendo os mesmos
TNSN06411A1 (en) Pyrimidine urea derivatives as kinase inhibitors
BRPI0312464B8 (pt) compostos inibidores de tirosina quinases, composições farmacêuticas compreendendo os mesmos, processos para fabricação e usos dos mesmos
MX2009002010A (es) Derivados de heteroarilo como inhibidores de la proteina cinasa.
ATE377597T1 (de) Anilinochinazoline als protein-tyrosin- kinasehemmer
NO20061327L (no) Kinazolinderivater
BRPI0511975A (pt) pirazolopirimidinas
MX2009005011A (es) Imidazopirazinas como inhibidores de proteina quinasa.
BRPI0510453A (pt) composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central
TW200624431A (en) Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
TW200512205A (en) Quinazoline derivatives
ATE499372T1 (de) Azabenzimidalzolderivate, ihre herstellung und ihre verwendung als antikrebsmittel
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
DE60215682D1 (de) AZAOXOINDOL DERIVATE ALS Trk PROTEIN KINASE HEMMSTOFFE ZUR BEHANDLUNG VON KREBS UND CHRONISCHEM SCHMERZ
ATE439361T1 (de) 7h-pyridoä3,4-düpyrimidin-8-one, ihre herstellung und ihre verwendung als proteinkinaseinhibitoren
BR0310081A (pt) Diaminotiazóis úteis como inibidores seletivos de cdk4
ATE507218T1 (de) Benzodiazepin-derivate als rock-kinasen hemmer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.